secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0001558370-25-007074
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants RMAT designation to MeiraGTx's AAV-GAD for Parkinson's disease
-------------------------------------------------------------------------

- RMAT designation based on data from three clinical studies (Phase 1 n=12, Phase 2 n=45, dose-ranging n=14).
- AAV-GAD showed significant benefit on UPDRS Part 3 motor endpoint in double-blind sham-controlled trials.
- Hologen AI analysis indicated disease-modifying brain circuitry changes, first in sham-controlled Parkinson's study.
- RMAT includes Fast Track and Breakthrough Therapy benefits, rolling review, and potential Priority Review for BLA.
- MeiraGTx plans to work closely with FDA to advance this one-time gene therapy for Parkinson's disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837025007074/0001558370-25-007074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837025007074/mgtx-20250509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-007074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer